Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 23;11:521–528. doi: 10.2147/OTT.S155581

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 Ruan et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Forest plots of hazard ratios for progression-free survival (A and C) and overall survival (B and D). In patients with epithelial ovarian cancer treated with bevacizumab plus chemotherapy, compared with chemotherapy alone, as chemotherapy regimens of carboplatin plus paclitaxel or not (A and B). In patients with epithelial ovarian cancer with high risk of progression (FIGO stage IV disease or FIGO stage III disease and >1.0 cm of residual disease after debulking surgery) treated with bevacizumab plus chemotherapy, compared with chemotherapy alone, as chemotherapy regimens of carboplatin plus paclitaxel or not (C and D).

Abbreviations: CI, confidence interval; PC, paclitaxel and carboplatin; PFS, progression-free survival; OS, overall survival; bev, bevacizumab; con, control; FIGO, International Federation of Gynecology and Obstetrics; IV, inverse variance.

Forest plots of hazard ratios for progression-free survival (A and C) and overall survival (B and D). In patients with epithelial ovarian cancer treated with bevacizumab plus chemotherapy, compared with chemotherapy alone, as chemotherapy regimens of carboplatin plus paclitaxel or not (A and B). In patients with epithelial ovarian cancer with high risk of progression (FIGO stage IV disease or FIGO stage III disease and >1.0 cm of residual disease after debulking surgery) treated with bevacizumab plus chemotherapy, compared with chemotherapy alone, as chemotherapy regimens of carboplatin plus paclitaxel or not (C and D).

Abbreviations: CI, confidence interval; PC, paclitaxel and carboplatin; PFS, progression-free survival; OS, overall survival; bev, bevacizumab; con, control; FIGO, International Federation of Gynecology and Obstetrics; IV, inverse variance.